1
|
Banerjee S, Kejriwal S, Ghosh B, Lanka G, Jha T, Adhikari N. Fragment-based investigation of thiourea derivatives as VEGFR-2 inhibitors: a cross-validated approach of ligand-based and structure-based molecular modeling studies. J Biomol Struct Dyn 2024; 42:1047-1063. [PMID: 37029768 DOI: 10.1080/07391102.2023.2198039] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Accepted: 03/26/2023] [Indexed: 04/09/2023]
Abstract
Angiogenesis is mediated by the vascular endothelial growth factor (VEGF) that plays a key role in the modulation of progression, invasion and metastasis, related to solid tumors and hematological malignancies. Several small-molecule VEGFR-2 inhibitors are marketed, but their usage is restricted to specific cancers due to severe toxicities. Therefore, cost-effective novel small molecule VEGFR-2 inhibitors may be an alternative to overcome these adverse effects. Here, a set of thiourea-based VEGFR-2 inhibitors were considered for a combined fragment-based QSAR technique, structure-based molecular docking followed by molecular dynamics simulation studies to acquire insights into the key structural attributes and the binding pattern of enzyme-ligand interactions. Noticeably, amine-substituted quinazoline phenyl ring and a higher number of nitrogen atoms, and the hydrazide function in the molecular structure are crucial for VEGFR-2 inhibition whereas methoxy groups are detrimental to VEGFR-2 inhibition. The MD simulation study of sorafenib and thiourea derivatives explored the significance of urea and thiourea moiety binding at VEGFR-2 active site that can be utilized further in the future to design molecules for greater binding stability and better VEGFR-2 selectivity. Therefore, such findings can be beneficial for the development of newer VEGFR-2 inhibitors for further refinement to acquire better therapeutic efficacy.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Suvankar Banerjee
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
| | - Shristi Kejriwal
- Indian Institute of Science Education and Research (IISER) Kolkata, Nadia, West Bengal, India
| | - Balaram Ghosh
- Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Shamirpet, Hyderabad, India
| | - Goverdhan Lanka
- Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad Campus, Shamirpet, Hyderabad, India
| | - Tarun Jha
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
| | - Nilanjan Adhikari
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
| |
Collapse
|
3
|
Bilici A, Koca S, Karaagac M, Aydin SG, Eraslan E, Kaplan MA, Ocak B, Goksu SS, Paydas S, Akgul F, Derin S, Ergun Y, Yekeduz E, Erol C, Ozyukseler DT, Demiray AG, Karaca M, Guc ZG, Menekse S, Cinkir HY, Gumusay O, Sakin A, Ozkul O, Demir H, Erdem D, Besiroglu M, Unal OU, Acar R, Koral L, Sahin S, Sakalar T, Bahceci A, Ozveren A, Gunaydin UM, Seker MM, Sunar V, Dal P, Artac M, Turhal S. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study. J Cancer Res Clin Oncol 2023:10.1007/s00432-023-04766-3. [PMID: 37067546 DOI: 10.1007/s00432-023-04766-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 04/08/2023] [Indexed: 04/18/2023]
Abstract
AIM Description of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS). PATIENTS AND METHODS This multicenter study is based on retrospective review of hospital medical records of patients (≥ 18 years) treated with pazopanib for non-adipocytic metastatic STS at 37 Oncology clinics across Turkey. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated with further analysis of data on the three most common histological subtypes (leiomyosarcoma [LMS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma [SS]) in the cohort. RESULTS Data of 552 adults (57.6% women, median age: 52 years) were analyzed. DCR and ORR were 43.1% and 30.8%, respectively. Median PFS was 6.7 months and OS was 13.8 months. For LMS, UPS and SS, median PFSs were 6.1, 5.9 and 7.53 months and median OSs were 15.03, 12.87 and 12.27 months, respectively. ECOG ≥ 2 was associated with poor PFS and OS. Liver metastasis was only a factor for progression. Second-line use of pazopanib (vs. front-line) was associated with better PFS, its use beyond third line predicted worse OS. Adverse events (AE) occurred in 82.7% of patients. Most common AEs were fatigue (58.3%) and anorexia (52.3%) which were graded as ≥ 3 in 8.2% and 7.4% of patients, respectively. CONCLUSION Pazopanib is effective and well-tolerated in treatment of non-adipocytic metastatic STS. Its earlier use (at second-line), good performance status may result in better outcomes. Worldwide scientific collaborations are important to gain knowledge on rarer STS subtypes by conducting studies in larger patient populations.
Collapse
Affiliation(s)
- Ahmet Bilici
- Medical Faculty, Department of Medical Oncology, Medipol University, TEM Avrupa Otoyolu Goztepe Cikisi, No:1, Bagcilar, 34214, Istanbul, Turkey.
| | - Sinan Koca
- Medical Faculty, Department of Medical Oncology, Marmara University, Istanbul, Turkey
| | - Mustafa Karaagac
- Meram Medical Faculty, Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey
| | - Sabin Goktas Aydin
- Medical Faculty, Department of Medical Oncology, Medipol University, TEM Avrupa Otoyolu Goztepe Cikisi, No:1, Bagcilar, 34214, Istanbul, Turkey
| | - Emrah Eraslan
- Department of Medical Oncology, Dr.Abdurrahman Yurtarslan Oncology Education and Research Hospital, Ankara, Turkey
| | - Muhammed Ali Kaplan
- Medical Faculty, Department of Medical Oncology, Dicle University, Diyarbakir, Turkey
| | - Birol Ocak
- Medical Faculty, Department of Medical Oncology, UludagUniversity, Bursa, Turkey
| | - Sema Sezgin Goksu
- Medical Faculty, Department of Medical Oncology, Akdeniz University, Antalya, Turkey
| | - Semra Paydas
- Medical Faculty, Department of Medical Oncology, Cukurova University, Adana, Turkey
| | - Fahri Akgul
- Medical Faculty, Department of Medical Oncology, Trakya University, Edirne, Turkey
| | - Sumeyye Derin
- Cerrahpasa Medical Faculty, Department of Medical Oncology, Istanbul University-Cerrahpasa, Istanbul, Turkey
| | - Yakup Ergun
- Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey
| | - Emre Yekeduz
- Medical Faculty, Department of Medical Oncology, Ankara University, Ankara, Turkey
| | - Cihan Erol
- Medical Faculty, Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara, Turkey
| | - Deniz Tataroglu Ozyukseler
- Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey
| | - Atike Gokcen Demiray
- Medical Faculty, Department of Medical Oncology, Pamukkale University, Denizli, Turkey
| | - Mustafa Karaca
- Department of Medical Oncology, Antalya Kartal Education and Research Hospital, Antalya, Turkey
| | - Zeynep Gulsum Guc
- Medical Faculty, Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkey
| | - Serkan Menekse
- Department of Medical Oncology, Manisa State Hospital, Manisa, Turkey
| | - Havva Yesil Cinkir
- Medical Faculty, Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey
| | - Ozge Gumusay
- Medical Faculty, Department of Medical Oncology, Acibadem University, Istanbul, Turkey
| | - Abdullah Sakin
- Medical Faculty, Department of Medical Oncology, Yuzuncuyil University, Van, Turkey
| | - Ozlem Ozkul
- Department of Medical Oncology, Sakarya Education and Research Hospital, Sakarya, Turkey
| | - Hacer Demir
- Medical Faculty, Department of Medical Oncology, Afyon Kocatepe University, Afyon, Turkey
| | - Dilek Erdem
- Medical Faculty, Department of Medical Oncology, Bahcesehir University, Samsun, Turkey
| | - Mehmet Besiroglu
- Medical Faculty, Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey
| | - Olcun Umit Unal
- Department of Medical Oncology, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey
| | - Ramazan Acar
- Department of Medical Oncology, Gulhane Education and Research Hospital, Ankara, Turkey
| | - Lokman Koral
- Medical Faculty, Department of Medical Oncology, Canakkale Onsekiz Mart University, Canakkale, Turkey
| | - Suleyman Sahin
- Department of Medical Oncology, Van Education and Research Hospital, Van, Turkey
| | - Teoman Sakalar
- Department of Medical Oncology, Aksaray Education and Research Hospital, Aksaray, Turkey
| | - Aykut Bahceci
- Department of Medical Oncology, Gaziantep Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey
| | - Ahmet Ozveren
- Department of Medical Oncology, Giresun Prof. Dr. A. Ilhan Ozdemir Education and Research Hospital, Giresun, Turkey
| | - Ulug Mutlu Gunaydin
- Medical Faculty, Department of Medical Oncology, Istanbul Medeniyet University, Istanbul, Turkey
| | | | - Veli Sunar
- Department of Medical Oncology, Zekai Tahir Burak Education and Research Hospital, Ankara, Turkey
| | - Pinar Dal
- Department of Medical Oncology, Eskisehir Education and Research Hospital, Eskisehir, Turkey
| | - Mehmet Artac
- Meram Medical Faculty, Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey
| | - Serdar Turhal
- Anadolu Medical Center, Department of Medical Oncology, Istanbul, Turkey
| |
Collapse
|
6
|
Alshamsan B, Badran A, Alshibany A, Maraiki F, Elshenawy MA, Elhassan T, Atallah JP. Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma. Cancer Manag Res 2021; 13:6755-6766. [PMID: 34512015 PMCID: PMC8414075 DOI: 10.2147/cmar.s323499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Accepted: 08/16/2021] [Indexed: 11/23/2022] Open
Abstract
Purpose Pazopanib has been approved for treating soft tissue sarcomas (STS) after chemotherapy. We aimed to evaluate the prognostic factors, clinical outcomes, and tolerability of pazopanib in patients with STS. Patients and Methods Forty-five patients treated between June 2015 and August 2019 were reviewed. Clinical outcome was measured by assessing the disease control rate (DCR) using Response Evaluation Criteria in Solid Tumors (version 1.1). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Adverse effects were assessed using the Common Terminology Criteria for Adverse Events (version 5.0). Results The median age of patients at diagnosis was 28 (interquartile range (IQR), 23–45) years. Pazopanib was used as the second-line treatment in 46.7% and the subsequent line in 53.3% of patients. The overall DCR was 55.6%, and at 8 and 12 weeks, it was 52.3% and 35.5%, respectively; the median duration of response was 7 (IQR: 2–18) months. Pazopanib-induced hypothyroidism was associated with DCR, with an odds ratio of 7 (95% confidence interval [95% CI: 1.7–27.5], p<0.01). The median PFS and OS were 4.1 (95% CI: 0.85–7.42) and 12.4 months (95% CI: 6.5–18.36), respectively. Hypothyroidism and response to pazopanib, better ECOG PS, histological subtypes desmoid tumor/aggressive fibromatosis (DT/AF), and alveolar soft part sarcoma (ASPS) were favorable prognostic factors for PFS. Hypothyroidism and response to pazopanib were significant favorable factors for OS. There was no statistical difference in the OS between patients using pazopanib as the second-line therapy and those using it as the subsequent-line therapy. Conclusion Pazopanib is an effective treatment for STS. However, it showed variability in the clinical outcome in favor of ASPS and an outstanding response in the DT/AF subtype. Pazopanib-induced hypothyroidism is a good prognostic factor for disease control and is associated with prolonged PFS and OS.
Collapse
Affiliation(s)
- Bader Alshamsan
- Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.,Department of Medicine, College of Medicine, Qassim University, Buraydah, Qassim, Saudi Arabia
| | - Ahmad Badran
- Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.,Clinical Oncology Department, Ain Shams University Hospitals, Ain Shams, Cairo, Egypt
| | - Aisha Alshibany
- Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Fatma Maraiki
- Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Mahmoud A Elshenawy
- Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.,Clinical Oncology, Faculty of Medicine - Menoufia University, Shebeen El-Kom, Shibin el Kom, Menoufia Governorate, Egypt
| | - Tusneem Elhassan
- Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Jean Paul Atallah
- Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| |
Collapse
|